Atropos Health Partners with Merck for Real-World Evidence
Palo Alto, Calif.-based Atropos Health has announced a strategic partnership with Merck to expedite the generation of real-world evidence (RWE). This collaboration aims to facilitate the rapid replication of studies and the production of valuable insights from real-world data.
Through this partnership, Atropos Health will enable rapid cohort creation and advanced analytics, allowing for publication-grade studies to be completed in less than 48 hours.
Merck’s data science and RWE teams will utilize Atropos Health’s innovative services, including the GENEVA OS (Generative Evidence Acceleration Operating System), Green Button, Atropos Evidence Network, and others, to enhance their research capabilities.
Brigham Hyde, CEO and cofounder of Atropos Health, stated, ‘Global life sciences organizations are relying on RWE for decision-making when it comes to the innovation of life-saving treatments. With the Atropos Health platform, Merck can now leverage automation and rapid evidence generation into their development of new treatments.’
The Larger Trend in Life Sciences
In a related development, Atropos secured $33 million in Series B funding in 2024, led by Valtruis and joined by investors such as McKesson Ventures and Merck GHI Fund.
Earlier this year, Atropos also partnered with Arcadia to enrich its health portfolio, aiming to provide users access to Atropos’ offerings for enhanced clinical decision-making.
Merck’s Commitment to Innovation
In recent years, Merck has actively sought partnerships to advance its capabilities in AI-driven drug discovery, including agreements with Standigm in South Korea and AION Labs in Israel.
Comments are closed